Trials / Withdrawn
WithdrawnNCT00327626
Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of ISIS 113715 Administered Daily in Patients With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Ionis Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to evaluate the safety, tolerability, and pharmacokinetics of two ISIS 113715 subcutaneous doses (15 mg and 30 mg/day) in combination with oral antidiabetic agents (OAD) versus OAD + placebo in patients with inadequately controlled type 2 diabetes, despite ongoing maximal treatment with OAD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ISIS 113715 |
Timeline
- Start date
- 2006-05-01
- Primary completion
- 2007-02-01
- Completion
- 2007-03-01
- First posted
- 2006-05-18
- Last updated
- 2022-12-05
Locations
5 sites across 1 country: Israel
Source: ClinicalTrials.gov record NCT00327626. Inclusion in this directory is not an endorsement.